The risk of new-onset diabetic retinopathy (DR) increased slightly, but significantly, in patients taking GLP-1 receptor ...

In a separate study, an implant containing a different investigational endothelin antagonist (PER-001) reduced macular ...

About AXPAXLI AXPAXLI™ (also known as OTX-TKI) is an investigational, bioresorbable, intravitreal hydrogel incorporating axitinib, a small molecule, multi-target, tyrosine kinase inhibitor with ...

The agreement is for a planned clinical trial of AXPAXLI (also known as OTX-TKI) for the treatment of non-proliferative ...

For example, mesangial proliferative glomerulonephritis, diffuse proliferative glomerulonephritis, crescentic glomerulonephritis, and a sclerosing glomerulopathy can be present in both C3GN and ...

WAIKOLOA, Hawaii — Katherine E. Talcott, MD, gave an overview on managing vitreous hemorrhage in proliferative diabetic retinopathy at Retina 2022.Talcott said that performing surgery for ...

In patients with diabetic macular edema in both eyes, the port delivery system in one eye achieves a superior anatomical ...

FORT LAUDERDALE, Fla. — Early pars plana vitrectomy may be a low-cost, definitive treatment for patients with proliferative diabetic retinopathy, according to a speaker at the Retina World Congress.

The broad histologic classifications included nonproliferative disease in 6061 (66.7 percent), proliferative disease without atypia in 2690 (29.6 percent), and atypical hyperplasia in 336 (3.7 ...

Conclusions: Ca 2+ is a necessary mediator of AM RF EMF anti-proliferative effects in HCC, which modulate the IP3/DAG signaling pathway (Costa, F. P., et al, 2011. "Treatment of advanced ...